Abstract
Introduction

52
Pregnancies affected by gestational diabetes mellitus (GDM) are characterized by various 53 degrees of maternal glucose intolerance, hyperglycemia and hyperinsulinemia (6). Several 54 epidemiological studies have shown that GDM is independently associated with adverse perinatal 55 outcomes (9, 36, 42) . The main adverse outcome of maternal diabetes is fetal macrosomia, which is 56 characterized by fetal fat accretion and overgrowth (27, 42) . The HAPO (Hyperglycemia and 57
Adverse Pregnancy Outcome) Study Cooperative Research Group has demonstrated an association 58
between maternal hyperglycemia and fetal macrosomia (1, 26) , suggesting that maternal 59 hyperglycemia is a contributing factor to fetal macrosomia by enhancing substrate availability to the 60 fetus, stimulating excessive growth and formation of adipose tissue (13, 34) . 61
The underlying mechanisms by which maternal hyperglycemia translate into fetal adiposity are 62 incompletely understood. In 1954, Pedersen proposed that maternal hyperglycemia results in 63 augmented transplacental glucose transfer leading to hyperglycemia in the fetus, which stimulates 64 the production and secretion of insulin by the fetal pancreatic beta-cells. Hence, glucose surplus and 65 hyperinsulinemia would play a direct role in the accumulation of fat in fetal adipose tissue (30, 31) . 66
However, Szabo et al. proposed a different hypothesis to explain fetal macrosomia in diabetic 67
women. The hypothesis postulates that high maternal plasma free fatty acids levels (NEFA), 68 secondary to maternal insulin resistance, lead to increased transplacental transfer of NEFA to the 69 fetus, which are subsequently transported to fetal adipocytes and esterified into triglycerides. In this 70 scenario, maternal hyperglycemia does not contribute directly to fetal fat accretion in the form of 71 energy oversupply, but rather maternal glucose is used as a source of the glycerol, necessary for 72 measured by standard enzymatic methods by C-711 using between 2-3 µl of sample. Low-120 density lipoprotein cholesterol (LDL-c) was calculated using the Friedewald-Fredrickson 121
formula. 122
Placental explants culture 123
Term placenta obtained from elective Caesarean section was placed on ice and arrived to the 124 laboratory within 10-15 minutes of delivery. Then, decidual tissue and large vessels were removed 125 from villous placenta by blunt dissection on aseptic culture conditions. Afterwards, small fragments 126 of villous tissues (~100 mg wet weight) were rinsed twice in cold-PBS and 6 explants were 127 transferred to each well of a 6-well plate containing 2 ml of culture medium (RPMI-1640 128 supplemented with 5 mmol/l glucose, 10% FBS (vol/vol), 100 units/ml penicillin G, and 100 µg/ml 129 streptomycin) and maintained at 37ºC in a humidified atmosphere of 5% CO 2 / 95% O 2 for 1h prior 130 to experiments. Villous explant viability and morphological integrity was assessed by XTT (XTT 131 kit, Roche) and haematoxylin-eosin staining respectively. 132
Materials 133
Cell culture reagents (RPMI-1640 medium without glucose and fetal bovine serum) were from 134 Invitrogen/Gibco, California, USA. The [9, 
Fatty acid solution preparation 138
Stock of fatty acid solution was prepared by conjugating palmitate with essentially fatty acid-139 free bovine serum albumin (BSA) to generate a stock solution of 25% (wt/vol) BSA, 4 mmol/l 140 palmitate in glucose-free culture medium. Stock solution was filtered-sterilized and diluted into the 141 final culture medium to give concentrations of 1.25% BSA, 0.1 or 0.2 mmol/l palmitate. 142
Fatty acid oxidation assay in placental explants 143
Mitochondrial FAO assays were performed ex vivo in placental explants as described 144 previously (2, 32) with the following modifications. Freshly isolated villous explants were 145 incubated in culture media supplemented with low (5 mmol/l) or high (11 mmol/l) glucose 146 concentrations, and in the presence of 1.25% BSA, 0.1 mmol/l cold palmitate, and 18500 Bq/ml 147 [ 3 H]-Palmitate at 37ºC for 18h. The glucose concentration in culture medium for the experiments in 148 which glucose was not an experimental factor was 5 mmol/l. Glucose was added to media from a 149 sterile stock solution of 1 mol/l glucose. At the end of the incubation period, the medium was 150 collected, and tritiated water determined by the vapor-phase equilibration method of Hughes et al 151 (21). FAO was defined as nmol of palmitate per mg of tissue per hour. 152
Esterification into total lipids in placental explants 153
The esterification rate in placental explants was determined as previously described with some 154 modifications (5). Briefly, after similar incubation conditions to those used for measurements of β-155 oxidation, with low or high glucose levels in the presence of 1.25% BSA, 0.1 mmol/l cold 156 palmitate, and 18500 Bq/ml [ 3 H]-palmitate for 18h, explants were washed 3 times with 2 ml of ice-157 cold PBS and homogenized in 500 µl of PBS. An aliquot of 100 µl was used to extract the lipid 158 content from samples according to Bligh and Dyer (3) . Afterwards, the radioactive content was 159 determined by liquid scintillation counting. Esterification was defined as nmol of palmitate per mg 160 of tissue per hour. 161
De novo lipid synthesis in placental explants 162
De novo lipid synthesis was determined using [
14 C]-glucose according to the procedure 163 described by Brown et al. with some modifications (5). Villous Placental explants from control 164 group were incubated in RPMI-1640 culture media with low-or high-glucose levels (5 mmol/l and 165 11 mmol/l respectively) and 37000 Bq/ml [ 14 C]-glucose at 37ºC for 18h. At the end of the 166 incubation period, culture media were discarded and explants collected, rinsed 3 times with 2 ml of 167 ice-cold PBS, followed by homogenization in 500 µl of PBS. After a total lipid extraction (as 168 described for measurements of placental esterification rate), the radioactive content was determined. 169
De novo lipid synthesis is expressed as pmol per mg of tissue per hour. 170
Placental triglyceride determination 171
Placental triglyceride determination was determined as previously described (33). Frozen 172 placental explants from control and GDM group (~20 mg) were used for experiments showed in 173 Figure 1 . For the rest of the experiments, placental explants were preincubated in low or high-174 glucose in the presence of 0.1 mmol/l palmitate for 18h as described above. Tissues were 175 homogenized in 400 µl HPLC-grade acetone. After incubation with agitation at room temperature 176 overnight, aliquots of 5 µl of acetone-extracted lipid suspension were used to determined 177 triglyceride concentrations using a triglyceride reagent kit (Biosystems, Barcelona, Spain). Proteins 178 were quantified using the bicinchoninic acid method (Thermo Scientific, Madrid, Spain). Placental 179 lipid content was defined as mg of triglyceride per mg of total placental proteins. 180
Western blot analysis 181
Placental explants from control group were preincubated in RPMI-1640 culture media 182 containing low-or high-glucose levels for 18h. At the end of the incubation period culture media 183 were discarded, explants were collected and washed with ice-cold PBS, followed by 184 homogenization in lysis buffer (20 mmol/l Tris-HCl pH 7.5, 150 mmol/l NaCl, 1 mmol/l EDTA, 1 185 mmol/l EGTA, 1% (v/v) Triton X-100, 2.5 mmol/l sodium pyrophosphate, 1 mmol/l β-186 glycerophosphate, 1 mmol/l Na 3 VO 4 , 1 µg/ml leupeptin, 1 mmol/l phenylmethylsulfonyl fluoride) ) 187 plus protease inhibitors (Protease Inhibitor Cocktail, Sigma, St. Louis, MO). After 10 min. on ice, 188 extracts were sonicated and centrifugated at 18,000 X g for 10 minutes at 4ºC. Pellets were 189 
Mitochondrial citrate synthase assay 197
As an index of mitochondrial content, citrate synthase activity was measured using the Citrate 198
Synthase Assay kit (Sigma, St. Louis, USA) according to manufacturer's instructions, in placenta 199 from control and GDM group. Protein content was determined as above. Citrate synthase activity 200 was defined as nmol/ml/min. 201
CPT assay 202
Activities of carnitine palmitoyltransferase I (CPT-I) and carnitine palmitoyltransferase II 203 (CPT-II) were determined in the direction of acyl-carnitine formation, using [ 14 C]-carnitine as 204 substrate (4). Briefly, placental explants were preincubated in RPMI-1640 culture media containing 205 low-or high-glucose levels at 37ºC for 18h. At the end of the incubation period culture media were 206 discarded, explants were collected and washed with ice-cold PBS priory homogenization in lysis 207 buffer (5 mmol/l Tris-HCl, pH 7.2, 150 mmol/l KCl) with a glass homogenizer. For assay of CPT-I, 208 100 µl of cell homogenate, in which the mitochondria remain largely intact, was incubated in the 209 presence of 50 µmol/l palmitoyl-CoA, 500 µmol/l carnitine and 9250 Bq/ml [ 14 C]-carnitine, in a 210 30ºC shaking water bath for 10 min. For assay of CPT-II, a portion of the homogenate was adjusted 211 to 1 % (w/v) of the detergent octylglucoside, which solubilizes the mitochondrial membranes, 212 inactivating CPT-I and releasing CPT-II from the mitochondrial matrix in active form. Afterwards, 213 reactions were stopped by adding 500 µl 1.2 N HCl and palmitoyl-[
14 C]-carnitine was extracted by 214 adding 500 µl of 1-butanol. Radioactive content was determined by liquid scintillation counting. 215
Statistical analysis 216
Statistical analysis of data was performed using the SPSS software (SPSS, Inc., Chicago, IL). 217
Distributions were checked with a histogram and the Kolmogorov-Smirnov test. When a variable 218 was distributed normally, data were presented as mean ± S.D. In cases of non-normal distribution, 219 data were shown as median and interquartile range. Comparisons were done by using the Mann 220
Whitney's U test or ANOVA. Differences were considered significant at p<0.05. 221
Results
222
Reduced fatty acid oxidation and elevated triglyceride levels in placentas from women with 223
gestational diabetes 224
To reveal the metabolic characteristics of placentas from women with GDM, we determined the 225 FAO capacity in placental explants from control and diabetic women. As shown in Figure 1A , FAO 226 was reduced by ~30% in placentas of women with gestational diabetes compared with the control 227 group. A reduction in FAO capacity could be explained by a lower mitochondrial number in the 228 GDM group. However, as assessed by citrate synthase activity, mitochondrial content was similar 229 between placental explants from control and diabetic women, suggesting that the molecular 230 mechanism underlying reduced FAO capacity in diabetic group may be related to other factors 231 rather than to mitochondrial number (Fig1B). Coinciding with reduced FAO, triglyceride levels in 232 the GDM group were 3-fold higher compared to control group (Fig1C). Taken together, these 233 results indicate an association between reduced FAO capacity and accumulation of triglycerides in 234 placentas from diabetic women. 235
Effect of high-glucose levels on fatty acid oxidation and triglyceride levels in explants of 236 human placenta. 237
Maternal hyperglycemia is a hallmark of women with gestational diabetes. Therefore, it is 238 reasonable to hypothesize that the impaired ability of placentas from women with GDM to oxidize 239 fatty acids is a direct consequence of placental glucose surplus environment, leading to 240 accumulation of placental triglycerides. To test this hypothesis, we measured the effect of low-or 241 high-glucose levels on FAO in placental explants from control group. As shown in Figure 2A 
Etomoxir-mediated inhibition of fatty acid oxidation increases triglyceride accumulation in 252 placental explants 253
To gain further insight into the molecular mechanism by which high glucose levels alter 254 placental fatty acid partitioning, we used etomoxir, a specific and irreversible inhibitor of the 255 carnitine palmitoyltransferase I (CPT-I), to evaluate the impact of inhibition of mitochondrial fatty 256 acid entry on FAO, fatty acid esterification and the storage pool of triglycerides in placenta from 257 healthy women. Etomoxir treatment significantly inhibited FAO capacity in placental explants 258 (Fig3A), resulting in augmented esterification (Fig3B), and higher placental triglyceride content 259
(Fig3C). 260
High-glucose levels decreases carnitine palmitoyltransferase I activity in placental explants 261
We further investigated the mechanisms by which high-glucose reduced FAO capacity in 262 human placental explants. To this end, we measured the activity of CPT-I and CPT-II in placental 263 explants from control group preincubated in low-or high-glucose levels for 18h. As shown in 264 Figure 4A -B, high-glucose levels reduced by ~70% the activity of CPT-I, whereas CPT-II activity 265 remained unchanged as expected. Because malonyl-CoA is a physiological regulator of CPT-I 266 activity, we quantified the phosphorylation levels of ACC, the enzyme that catalyzes the ATP-267 dependent carboxylation of acetyl-CoA to form malonyl-CoA. Interestingly, phosphorylation levels 268 of ACC were reduced by ~25% in the presence of high-glucose levels ( Figure 4C ), suggesting an 269 increased production of malonyl-CoA in placental explants. 270
Discussion
271
The availability of maternal nutrients to the fetus is regulated by the placenta involving three 272 main mechanisms: direct transfer of nutrients, placental consumption of nutrients and placental 273 conversion of nutrients into alternative fuel sources (19). Direct transfer has been considered the 274 main mechanism by which placenta regulates the nutrient-exchange between the mother and the 275 fetus (19). However, the placenta exhibits a high metabolic activity, which is severely affected by 276 the intrauterine milieu of diabetic and/or obese women. Specifically, studies performed on placentas 277 from diabetic women have shown major changes in expression levels of genes involved up-278 regulation of pathways of lipid synthesis and transplacental lipid fluxes (16, 25, 34, 35) . These 279 findings have spurred the notion that alterations in placental lipid pathways perhaps contribute to 280 fetal fat accumulation and adiposity in diabetic women (8, 34) . 281
The FAO pathway has not been evaluated in placenta from GDM women. In this study, we 282 demonstrated that these women exhibited lower FAO oxidation capacity without change in 283 mitochondrial content. To explain these observations, we hypothesized that lower FAO capacity 284 may be related to maternal hyperglycemia, a hallmark of GDM women. However, the metabolic 285 environment of women with GDM is characterized also by the presence of excessive NEFA levels 286 and pro-inflammatory cytokines (6, 35), which makes difficult to tease apart the causing factor 287 involved in reduced placental FAO observed in these women. Thus, we attempted to mimic 288 maternal milieu of women with GDM in our ex vivo studies, using low-and-high glucose levels, and 289 low-and-high NEFA levels. Therefore, a limitation of this study is that although our ex vivo culture 290 conditions for placental explants clearly allowed mechanistic studies; they may not accurately 291 reflect a GDM milieu and replicate in vivo pathology. Thus, our findings in placenta from women 292 with GDM may be explained by other factors related to obesity, such as elevated NEFA and/or pro-293 inflammatory cytokines, rather than maternal hyperglycemia. However, obesity is not a 294 confounding factor in the phenotype of the GDM women group in our study population (BMI was 295 similar between both groups), which supports the notion that only GDM related factors, such as 296 higher glucose levels, may trigger the observed modifications. Although glycemia and insulinemia 297 levels were only determined in the fasting state, it may be highlighted that the absence of 298 differences between the two groups may be also attributed to the prescription of a strict metabolic 299 control in patients with GDM. Along this line, there were no differences in the levels of 300 glycosylated haemoglobin between the two groups. Nevertheless, further studies are warranted to 301 investigate regulation of FAO pathways using placental explants from women with type I diabetes, 302 type II diabetes, and obese non-diabetic women. Using placental explants from women with no pregnancy complication, we demonstrated that 307 high-glucose levels inhibited FAO and increased triglyceride accumulation. These results are in 308 agreement with our findings in placentas from GDM women. Because de novo fatty acid synthesis 309 remained unchanged, and because etomoxir-mediated inhibition of CPT-I recapitulated the effects 310 of high-glucose on FAO and esterification pathways, we thought that the mechanistic link between 311 high-glucose levels and lower FAO was inhibition of CPT-I activity by its physiological inhibitor 312 malonyl-CoA, which is synthesized from glucose-derived acetyl-CoA by ACC. Following this 313 rationale, we demonstrated that CPT-I activity and phosphorylation of ACC was significantly 314 decreased by high-glucose levels. Because phosphorylation of ACC inhibits its enzymatic activity, 315 our results support the notion that FAO is diminished by high-glucose levels through decreased 316 ACC phosphorylation and enhanced production of malonyl-CoA levels in placental explants, which 317 resulted in lower CPT-I activity. Interestingly, this mechanism results in a shift of fatty acid 318 partitioning away from the β-oxidation pathway towards esterification, allowing the accumulation 319 of triglycerides in human placenta. 320
These alterations in lipid metabolism mediated by high-glucose levels beg for two important 321 questions: 1) What are the consequences of triglycerides accumulation in placenta? 2) Is placental 322 storage of triglycerides a contributing factor to fetal macrosomia? Several studies have 323 demonstrated that maternal serum triglyceride levels are associated with abnormal fetal growth in 324 women with GDM, type 1 and type 2 diabetes (17, 38), spurring the notion that increased maternal 325 lipid availability results in fetal fat accretion. In a hypothetical scenario of maternal triglycerides 326 oversupply and elevated lipolysis rate at the maternal-placental side, esterification of NEFA into 327 triglycerides in placental cells may indicate a regulatory system to limit maternal fatty acids transfer 328 to the fetus, and serve as a protective mechanism against fetal macrosomia. However, there is no 329 data about the lipolysis rate of very low-density lipoproteins and chylomicron remnants in placentas 330 from women with GDM. Thus, although placental lipid metabolism has been proposed as a 331 regulatory step towards fetal macrosomia (14, 34, 39, 41) , it is still missing a direct evidence 332 demonstrating that unbalanced triglycerides storage in placental cells results in augmented 333 transplacental delivery of adipogenic substrates to the fetus. On the other hand, accumulation of 334 triglycerides or its harmful intermediaries, such as ceramide and diacylglycerol, in trophoblast cells 335 may exacerbate the basal pro-inflammatory state of pregnancy. In this hypothetical scenario, 336 accumulation of triglycerides in placental cells would trigger inflammatory pathways in trophoblast 337 cells and deleterious effects on placental and fetal metabolism. Several studies support the idea that 338 GDM and/or obesity induces inflammatory pathways in placenta (7, 12, 24, 35) . 339
Our results on fatty acid partitioning contrast with early studies performed by Pathmapeura et 340 al. in trophoblast isolated from normal term human placentas. They showed that low-or high-341 glucose (0,5-18 mmol/L) levels had not significant effects on FAO and esterification processes in 342 cultured trophoblast exposed to short (2h) or longer (24h) periods of time (29). The differences 343 between both studies may be explained by the experimental models employed. Firstly, Pathmapeura 344 et al. used cultured trophoblast isolated from human placentas, whereas we used placental explants. 345
The latter technique allows the possibility to investigate trophoblast function in a context that 346 contains other cell types (fibroblasts, macrophages, endothelial cells, etc.) and retains the cellular 347 architecture of the tissue in vivo. Secondly, trophoblast cells were maintained in culture media for 348 16h prior initiation of experimental procedures, whereas placental explants were only maintained in 349 culture media for 1h. Finally, they investigated the effects of glucose levels on fatty acid 350 partitioning for 24h in the presence of 0.25 mmol/l non-esterified fatty acids (palmitate:oleate ratio 351 1:1), whereas we used 0.2 mmol/l palmitate as a source of non-esterified fatty acids. 352
We showed that placenta from healthy women can incorporate [
14 C]-glucose into lipids, 353 corroborating previous studies concerning the de novo fatty acid synthesis capacity of human 354 placenta (10, 20, 40) . Whereas high-glucose did not result in a significant increase in de novo lipid 355 synthesis in placental explants, FAO was decreased, suggesting an increase in glucose-derived 356 malonyl-CoA. Under these experimental conditions ACC activity appeared to function primarily as 357 a regulator of the FAO pathway, rather than a regulator of the de novo fatty acid synthesis pathway. 358
A similar role for ACC has been described in tissues with low de novo fatty acid synthesis capacity, 359 such as skeletal and cardiac muscle (37). Early studies suggested that de novo fatty acid synthesis 360 pathway plays a minor role in triglyceride accumulation in diabetic placenta, consistent with our 361 observation on ex vivo metabolism (10, 20, 39, 40) . Finally, we acknowledge that a limitation of our 362 study is that placental explants were preincubated in the absence of insulin, which is present in the 363 in vivo milieu and it is required for de novo lipid synthesis. Therefore, taken into consideration our 364 experimental conditions without insulin and given the non-significant trend towards increased 365 [ 14 C]-glucose incorporation into lipid in the presence of high glucose, we cannot conclude that 366 elevations in glucose do not increase placental de novo lipid synthesis in vivo. 367
In conclusion, we demonstrate that high-glucose levels alter the metabolic partitioning of fatty 368 acids in human placenta, shifting flux of fatty acids away from oxidation towards the esterification 369 pathway, leading to accumulation of placental triglycerides. The mechanistic link between high-370 glucose levels and lower FAO capacity is through reduced activity of the enzyme CTP-I, which 371 regulates the first step of the entry of long-chain acyl-CoA into the mitochondrial matrix for β-372 oxidation. These findings shed light on the biochemical mechanisms by which maternal 373 hyperglycemia may regulate placental lipid pathways in diabetic mothers. pregnancy complication (control group, n=8) and gestational diabetic women (GDM, n=8) were 508 used to obtain villous explants as described in "Methods" section. The explants were preincubated 509 with 0.1 mmol/l (18500 Bq/ml) palmitate for 18 hours, and the production of Frozen placental tissues (~100 mg) from control (n=8) and GDM group (n=8) were used to quantify 516 placental triglyceride content as described in the "Methods" section. Values are Mean ± S.D. for 8 517 independent experiments in triplicate. *p<0.05 relative to control group. 518 Figure 2 . High-glucose levels inhibit fatty acid oxidation in placentas from healthy women. 519 (a) Effect of high-glucose levels on fatty acid oxidation. A subset of 6 placentas from women with 520 no pregnancy complication described in table 1 was used to obtain villous explants. Placental 521 explants from control group were incubated at 5 (5 Gl) or 11 (11 Gl) mmol/l glucose in the presence 522 of 0.1 (0.1 Pa) mmol/l palmitate for 18 hours. Afterwards, [
3 H]-water was determined as described 523 in the "Methods" section. Values are Mean ± S.D. for 6 independent experiments in triplicate. 524
Significance is indicated (*p<0.05) relative to 5 mmol/l glucose. (b) Effect of high-glucose levels 525 on fatty acid esterification. A subset of 6 placentas from women with no pregnancy complication 526 described in table 1 was used to measure the esterification capacity. Placental explants from control 527 group were incubated at 5 (5 Gl) or 11 (11 Gl) mmol/l glucose in the presence of 0.1 (0.1 Pa) or 0.2 528 concentrations of etomoxir. The same subset of placental explants described in panel A were used 551 to assess esterification into total lipids as described in the "Methods" section. Mean ± S.D. for 6 552 independent experiments in triplicate. *p<0.05 relative to untreated placental explants. (c) The same 553 subset of placental explants described in panel A were used to assess triglycerides content as 554 described in the "Methods" section. Mean ± S.D. for 6 independent experiments in triplicate. 555 *p<0.05 relative to untreated placental explants. 556 Figure 4 . High-glucose levels inhibit carnitine palmitoyltransferase I activity and reduce 557 phosphorylation levels of acetyl-CoA carboxylase. A subset of 6 placentas from women with no 558 pregnancy complication described in table 1 was used to obtain villous explants and perform the 559 following experiments. Carnitine palmitoyltransferase I activity (a) and carnitine 560 palmitoyltransferase II activity (b) were determined as described in the "Methods" section in 561 placental explants incubated at low (5 mmol/l) or high (11 mmol/l) glucose concentrations for 18 562 hours. Mean ± S.D. for 6 independent experiments in duplicate is shown. 
